Profile data is unavailable for this security.
About the company
Egetis Therapeutics AB (publ), formerly PledPharma AB (publ) is a Sweden-based pharmaceutical drug development company, focusing on projects in late-stage development for treatment of diseases with unmet medical needs in the orphan drug segment. The Company’s pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.
- Revenue in SEK (TTM)79.20m
- Net income in SEK-295.80m
- Incorporated2006
- Employees33.00
- LocationEgetis Therapeutics AB (publ)Klara Norra Kyrkogata 26STOCKHOLM 111 22SwedenSWE
- Phone+46 86797210
- Fax+46 86635725
- Websitehttps://www.egetis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intellego Technologies AB | 231.25m | 82.86m | 1.07bn | 62.00 | 12.43 | 4.59 | 11.83 | 4.63 | 3.03 | 3.03 | 8.50 | 8.20 | 0.8298 | 4.24 | 2.45 | 3,729,807.00 | 29.74 | -- | 37.90 | -- | 68.61 | -- | 35.83 | -- | 1.88 | 8.84 | 0.1532 | -- | 222.74 | -- | 493.56 | -- | -- | -- |
| Diamyd Medical AB | 130.00k | -151.85m | 1.22bn | 27.00 | -- | 8.24 | -- | 9,378.94 | -1.60 | -1.60 | 0.0014 | 1.46 | 0.0006 | -- | 3.17 | 4,814.82 | -71.82 | -34.32 | -83.67 | -38.45 | -10,161.54 | -3,111.20 | -116,806.90 | -17,499.13 | -- | -- | 0.1737 | -- | -76.19 | -39.23 | -30.82 | -- | -- | -- |
| XSpray Pharma AB (publ) | 0.00 | -258.05m | 1.30bn | 24.00 | -- | 2.46 | -- | -- | -7.81 | -7.81 | 0.00 | 17.14 | 0.00 | -- | -- | 0.00 | -37.64 | -18.38 | -40.48 | -19.26 | -- | -- | -- | -- | 1.51 | -- | 0.0543 | -- | -- | -- | -36.45 | -- | 2.87 | -- |
| Nightingale Health Oyj | 50.67m | -203.03m | 1.37bn | 86.00 | -- | 2.13 | -- | 27.00 | -0.2895 | -0.2895 | 0.0722 | 1.37 | 0.0441 | 2.33 | 3.46 | 50,674.42 | -17.67 | -14.59 | -18.99 | -15.99 | 66.45 | 77.90 | -400.71 | -435.73 | 9.74 | -- | 0.0308 | -- | 4.21 | 16.13 | 3.43 | -- | 8.54 | -- |
| Nanoform Finland Oyj | 26.68m | -251.91m | 1.39bn | 174.00 | -- | 1.69 | -- | 52.11 | -0.2707 | -0.2707 | 0.0285 | 0.829 | 0.0269 | 97.30 | 6.27 | 13,906.00 | -25.39 | -27.13 | -27.55 | -29.48 | -631.53 | -604.26 | -944.30 | -1,023.70 | 8.12 | -- | 0.0778 | -- | -26.41 | 61.31 | 5.98 | -- | 53.92 | -- |
| Cereno Scientific AB | 0.00 | -69.48m | 1.39bn | 5.00 | -- | 5.50 | -- | -- | -0.283 | -0.283 | 0.00 | 0.8998 | 0.00 | -- | -- | 0.00 | -23.45 | -16.81 | -25.41 | -18.26 | -- | -- | -- | -- | -- | -9.44 | 0.1519 | -- | -- | -- | -73.95 | -- | 44.79 | -- |
| Solar Foods Oyj | 201.37k | -124.29m | 1.48bn | 40.00 | -- | 4.51 | -- | 7,355.33 | -0.4438 | -0.4438 | 0.0007 | 1.15 | 0.0004 | -- | 0.0049 | 558.71 | -21.32 | -- | -24.11 | -- | 20,183.14 | -- | -61,719.29 | -- | -- | -2.71 | 0.4266 | -- | -- | -- | -66.44 | -- | -- | -- |
| Vicore Pharma Holding AB | 104.24m | -196.45m | 1.82bn | 29.00 | -- | 2.30 | -- | 17.48 | -1.72 | -1.72 | 0.9135 | 3.38 | 0.2045 | -- | 43.73 | 4,343,459.00 | -38.54 | -58.65 | -41.49 | -65.58 | -- | -- | -188.45 | -- | -- | -- | 0.00 | -- | -- | -- | -7.81 | -- | -- | -- |
| Egetis Therapeutics AB (publ) | 79.20m | -295.80m | 1.95bn | 33.00 | -- | 4.99 | -- | 24.63 | -1.07 | -1.07 | 0.2882 | 1.09 | 0.1425 | 23.00 | 3.61 | 2,933,333.00 | -48.67 | -33.02 | -61.23 | -36.46 | 85.48 | -- | -341.54 | -357.72 | 0.9808 | -19.71 | 0.2605 | -- | 154.87 | 15.35 | -68.68 | -- | -- | -- |
| Hansa Biopharma AB | 189.39m | -654.78m | 2.08bn | 135.00 | -- | -- | -- | 10.96 | -11.34 | -11.34 | 3.21 | -4.72 | 0.1794 | 34.61 | 1.25 | 1,127,321.00 | -62.01 | -47.96 | -86.68 | -56.12 | 53.43 | 64.18 | -345.73 | -835.04 | 2.44 | -41.44 | 1.50 | -- | -13.22 | 109.06 | -36.09 | -- | -35.24 | -- |
| Devyser Diagnostics AB | 198.00m | -71.40m | 2.20bn | 119.00 | -- | 6.28 | -- | 11.09 | -4.37 | -4.37 | 12.12 | 21.17 | 0.4019 | 1.97 | 5.29 | 1,677,966.00 | -14.51 | -8.97 | -16.40 | -10.15 | 80.00 | 80.14 | -36.11 | -23.91 | 3.81 | -- | 0.1492 | -- | 33.71 | 28.59 | -16.64 | -- | 44.59 | -- |
Data as of Nov 21 2024. Currency figures normalised to Egetis Therapeutics AB (publ)'s reporting currency: Swedish Krona SEK
14.73%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 30 Jun 2024 | 21.40m | 6.36% |
| Handelsbanken Fonder ABas of 31 Dec 2023 | 11.83m | 3.52% |
| Unionen (Investment Management)as of 31 Dec 2023 | 6.95m | 2.07% |
| Swedbank Robur Fonder ABas of 31 Oct 2024 | 5.51m | 1.64% |
| SEB Investment Management ABas of 31 Oct 2024 | 1.52m | 0.45% |
| FCG Fonder ABas of 31 Oct 2024 | 1.20m | 0.36% |
| Financi�re Arbevel SAas of 30 Dec 2022 | 500.00k | 0.15% |
| E. �hman J :or Fonder ABas of 31 May 2024 | 426.93k | 0.13% |
| Skandia Investment Management ABas of 30 Sep 2024 | 174.51k | 0.05% |
| Robious Capital LLCas of 30 Sep 2024 | 34.13k | 0.01% |
More ▼
Data from 30 Sep 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
